Charles T. Quinn, MD, MS

Director, Hematology Clinical and Translational Research

Director, Hemoglobinopathy Laboratory

Associate Professor, UC Department of Pediatrics

Phone 513-636-4266

Fax 513-636-5845


Clinical Interests

Sickle cell disease; thalassemia; hemoglobinopathies; anemia; autoimmune hemolytic anemia; disorders of red blood cells; iron overload and iron chelation; chronic transfusion therapy; immune thrombocytopenia (ITP); neutropenia; stroke

Research Interests

Epidemiology, pathophysiology, treatment and prevention of brain injury (structural and cognitive) in sickle cell disease; measurement of red blood cell turnover in sickle cell disease; identification and treatment of cardiomyopathy and nephropathy in sickle cell disease; treatment and prevention of pain (VOC) in sickle cell disease; MRI methods of iron quantitation; new agents for immune thrombocytopenia (ITP)

Dr. Quinn’s main interests and expertise are in patient-oriented and translational research in sickle cell disease and thalassemia. His formal clinical and translational research training has included: (1) the NIH-K30 Curriculum in Patient-Oriented Research; (2) the Clinical Research Training Institute of the American Society of Hematology; (3) the NIH-K12/KL2 Clinical Scholars Program; and (4) a master’s degree in clinical sciences. Dr. Quinn is a member of the Editorial Board for Pediatric Blood and Cancer and the Board of Contributing Editors for The Hematologist. Dr. Quinn is on the Medical Advisory Board for the Cooley’s Anemia Foundation, and he is a member of the Committee on Educational Affairs of the American Society of Hematology. Locally, he is the medical director of the Ohio Department of Health Regional Sickle Cell Services Program – Region 1.

MD:  University of Texas Southwestern Medical Center, Dallas, TX, 1994.

MS:  University of Texas Southwestern Medical Center, Dallas, TX, 2008.

Residency & Chief Residency: Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 1998.

Fellowship:  Children's Medical Center Dallas, Dallas, TX; University of Texas Southwestern Medical Center, Dallas, TX, 2001.

Certifications: Pediatrics, 1998; Pediatric Hematology-Oncology, 2002.

View PubMed Publications

DeBaun MR, Gordon M, McKinstry RC, Noetzel MJ, White DA, Sarnaik SA, Meier ER, Howard TH, Majumdar S, Inusa BP, Telfer PT, Kirby-Allen M, McCavit TL, Kamdem A, Airewele G, Woods GM, Berman B, Panepinto JA, Fuh BR, Kwiatkowski JL, King AA, Fixler JM, Rhodes MM, Thompson AA, Heiny ME, Redding-Lallinger RC, Kirkham FJ, Dixon N, Gonzalez CE, Kalinyak KA, Quinn CT, Strouse JJ, Miller JP, Lehmann H, Kraut MA, Ball WS Jr, Hirtz D, Casella JF. Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemiaN Engl J Med. 2014 Aug 21;371(8):699-710.

King AA, Rodeghier MJ, Panepinto JA, Strouse JJ, Casella JF, Quinn CT, Dowling MM, Sarnaik SA, Thompson AA, Woods GM, Minniti CP, Redding-Lallinger RC, Kirby-Allen M, Kirkham FJ, McKinstry R, Noetzel MJ, White DA, Kwiatkowski JK, Howard TH, Kalinyak KA, Inusa B, Rhodes MM, Heiny ME, Fuh B, Fixler JM, Gordon MO, DeBaun MR. Silent cerebral infarction, income, and grade retention among students with sickle cell anemia. Am J Hematol. 2014 Jul 15.

Vetter CL, Buchanan GR, Quinn CT. Burden of diagnostic radiation exposure in children with sickle cell disease. Pediatr Blood Cancer. 2014 Jul;61(7):1322-4.

Dowling MM, Noetzel MJ, Rodeghier MJ, Quinn CT, Hirtz DG, Ichord RN, Kwiatkowski JL, Roach ES, Kirkham FJ, Casella JF, DeBaun MR. Headache and migraine in children with sickle cell disease are associated with lower hemoglobin and higher pain event rates but not silent cerebral infarction. J Pediatr. 2014 May;164(5):1175-1180.e1.

Chandrakasan S, Bakeer N, Mo JQ, Cost C, Quinn CT. Iron-refractory microcytic anemia as the presenting feature of unicentric Castleman disease in children. J Pediatr. 2014 Apr;164(4):928-30.

King AA, Strouse JJ, Rodeghier MJ, Compas BE, Casella JF, McKinstry RC, Noetzel MJ, Quinn CT, Ichord R, Dowling MM, Miller JP, Debaun MR. Parent education and biologic factors influence on cognition in sickle cell anemia. Am J Hematol. 2014 Feb;89(2):162-7.

Quinn CT. Sickle cell disease in childhood: from newborn screening through transition to adult medical care. Pediatr Clin North Am. 2013 Dec;60(6):1363-81.

McCavit TL, Xuan L, Zhang S, Flores G, Quinn CT. National trends in incidence rates of hospitalization for stroke in children with sickle cell disease. Pediatr Blood Cancer. 2013 May;60(5):823-7.

Quinn CT, McKinstry RC, Dowling MM, Ball WS, Kraut MA, Casella JF, Dlamini N, Ichord RN, Jordan LC, Kirkham FJ, Noetzel MJ, Roach ES, Strouse JJ, Kwiatkowski JL, Hirtz D, DeBaun MR. Acute silent cerebral ischemic events in children with sickle cell anemia. JAMA Neurol. 2013 Jan;70(1):58-65.

Trachtenberg FL, Mednick L, Kwiatkowski JL, Neufeld EJ, Haines D, Pakbaz Z, Thompson AA, Quinn CT, Grady R, Sobota A, Olivieri N, Horne R, Yamashita R. Thalassemia Clinical Research Network. Beliefs about chelation among thalassemia patients. Health Qual Life Outcomes. 2012 Dec 7;10:148.

A feasibility study of regadenoson for the treatment of acute chest syndrome. Co-investigator. National Institutes of Health. April 2012-March 2017. P50HL110790.

Cincinnati Center of Excellence in Hemoglobinopathies Research. Co-PI. National Institutes of Health. Aug 2013–May 2018. U01 HL117709.

A Phase 3, Double-Blind, Randomized, Efficacy and Safety Comparison of Prasugrel and Placebo in Pediatric Patients with Sickle Cell Disease. Co-Investigator. Eli Lilly and Co. Jan 2013–Dec 2015.

Evaluation of Purified Poloxamer 188 in Children in Crisis (EPIC): A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Clinical Trail of ANX-188 (Purified Poloxamer 188) Injection in Children with Sickle Cell Disease Experiencing Vaso-Occlusive Crisis. Co-Investigator. MAST Therapeutics. Nov 2012–Dec 2015.

Safety and Efficacy Study of Romiplostim to Treat ITP in Pediatric Subjects. Co-Investigator. Amgen Inc. Oct 2013–Dec 2015.